Millendo Therapeutics, Inc. has entered into an license agreement with AstraZeneca PLC for the worldwide development and commercialization rights to AZD4901, a product candidate for the treatment of polycystic ovary syndrome (PCOS), an endocrine disease in women. Under the terms of the agreement, Millendo Therapeutics acquired global rights to develop and commercialize MLE4901. In exchange, AstraZeneca will receive an upfront payment and take an equity stake in Millendo Therapeutics, as well as development and commercial milestone payments.

In addition, AstraZeneca is eligible to receive royalties on net product sales.